Related Experiment Video
Updated: Jan 17, 2026
08:52
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
9.3K
Precision Medicine Program in Chinese Pediatric Patients With Sarcoma.
Suying Lu1, Yu Zhang2, Weiling Zhang3
1Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
JCO Precision Oncology
|January 14, 2026
Summary
This study analyzed Chinese pediatric sarcomas, finding most patients have molecular aberrations. These genetic changes correlate with treatment response and tumor characteristics, highlighting the need for molecular profiling.
Area of Science:
- Pediatric Oncology
- Molecular Pathology
- Genomics
Background:
- Molecular profiles of pediatric sarcomas in China are largely unknown.
- The Chinese Pediatric Precision Oncology Group (CPPOG) aims to define these profiles for improved diagnosis and treatment.
- This is the first report from the CPPOG trial on pediatric sarcomas.
Purpose of the Study:
- To characterize the molecular profiles of sarcomas in Chinese children.
- To identify subtype-specific somatic alterations and activated pathways.
- To correlate molecular features with treatment response and pathological characteristics.
Main Methods:
- Panel sequencing (830-gene DNA, 395-gene RNA) was performed on 214 tumors from 210 pediatric patients.
- Tumors were collected from 11 centers across China between April 2021 and January 2022.
- Prospective analysis focused on characterizing alterations, pathways, and subgroup features.
Main Results:
- 88.3% of tumors had at least one somatic or germline alteration; 51.4% had gene fusions.
- Actionable therapeutic targets were found in 46.3% of patients; 14.3% had modified diagnoses based on molecular findings.
- Common alterations included TP53 mutations and EWSR1-FLI1 fusions; TP53, PI3K, and RTK-RAS pathways were most activated. TP53 and NRAS mutations were higher in progressive disease.
Conclusions:
- The study provides the initial molecular landscape of Chinese pediatric sarcomas.
- Molecular alterations correlate with therapeutic responses and pathological characteristics.
- Panel sequencing is recommended for pediatric sarcoma diagnosis and treatment planning.
